Retension Pharmaceuticals COO reports stock options

Q: When do RTSN's Series A and Series B preferred shares convert?

Each preferred share is convertible into one common share at the holder’s option at any time. Both series will automatically convert immediately before the issuer’s initial public offering closes, without payment of consideration.

The Series A and Series B preferred shares are set to convert automatically immediately before Retension Pharmaceuticals' initial public offering closes.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Sabine Bisson, Chief Operating Officer of Retension Pharmaceuticals, Inc., reported direct holdings dated October 8, 2026: stock options covering 24,155 common shares at a $1.4300 exercise price, expiring September 22, 2034, and options covering 24,155 common shares at a $2.4300 exercise price, expiring October 30, 2035. She also reported 1,611 Series A and 2,504 Series B convertible preferred shares. Each preferred share is convertible into one common share, and both series will automatically convert immediately before the issuer’s initial public offering closes without payment of consideration.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Bisson Sabine

Role Chief Operating Officer

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy) ^F1	--	--	--
holding	Stock Option (right to buy) ^F2	--	--	--
holding	Series A Convertible Preferred Stock ^F3	--	--	--
holding	Series B Convertible Preferred Stock ^F4	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 48,310 contracts (Direct); Series A Convertible Preferred Stock — 1,611 contracts (Direct); Series B Convertible Preferred Stock — 2,504 contracts (Direct)

Footnotes (4)

F1. Granted to the Reporting Person on September 23, 2024. The stock options vest in 1/36 monthly increments, with the first vesting date on January 11, 2024, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F2. Granted to the Reporting Person on October 31, 2025. The stock options vest in 1/36 monthly increments, with the first vesting date on September 29, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F3. The Series A Convertible Preferred Stock (the "Series A Preferred Stock") is convertible into one share of Common Stock at any time at the option of the holder. The Series A Preferred Stock will automatically convert immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Series A Preferred Stock has no expiration date.
F4. The Series B Convertible Preferred Stock (the "Series B Preferred Stock") is convertible into one share of Common Stock at any time at the option of the holder. The Series B Preferred Stock will automatically convert immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Series B Preferred Stock has no expiration date.

Key Figures

Underlying common shares: 24,155 shares Exercise price: $1.4300 per share Underlying common shares: 24,155 shares +3 more

6 metrics

Underlying common shares 24,155 shares Stock option expiring September 22, 2034

Exercise price $1.4300 per share Stock option expiring September 22, 2034

Underlying common shares 24,155 shares Stock option expiring October 30, 2035

Exercise price $2.4300 per share Stock option expiring October 30, 2035

Series A preferred shares 1,611 shares Convertible into one common share per preferred share

Series B preferred shares 2,504 shares Convertible into one common share per preferred share

Key Terms

vest in 1/36 monthly increments, convertible preferred stock, automatically convert, without payment of consideration

4 terms

vest in 1/36 monthly increments financial

"stock options vest in 1/36 monthly increments"

convertible preferred stock financial

"Series A Convertible Preferred Stock"

Convertible preferred stock is a special class of company shares that pays priority, usually fixed, payments to holders and can be exchanged later for a set number of common shares. It matters to investors because it combines steady income and added protection with the chance to share in a company’s upside; think of it as a hybrid between a bond that pays regularly and an option to convert into growth-oriented stock, where the conversion rules influence both potential gains and how much common shareholders’ ownership may be reduced.

automatically convert financial

"will automatically convert immediately prior"

without payment of consideration financial

"convert ... without payment of consideration"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What options does Sabine Bisson hold in RTSN?

Sabine Bisson reported two direct stock-option holdings, each covering 24,155 common shares: one has a $1.4300 exercise price and expires September 22, 2034, and the other has a $2.4300 exercise price and expires October 30, 2035.

When do RTSN's Series A and Series B preferred shares convert?

Each preferred share is convertible into one common share at the holder’s option at any time. Both series will automatically convert immediately before the issuer’s initial public offering closes, without payment of consideration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/13/2026 - 08:14 PM EDT Accepted by SEC EDGAR 10/08/2026 - 06:36 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bisson Sabine

(Last)

(First)

(Middle)

1104 WEST BROAD STREET

SUITE 1029

(Street)

FALLS CHURCH

VIRGINIA

22046

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/08/2026

3. Issuer Name and Ticker or Trading Symbol
Retension Pharmaceuticals, Inc. [ RTSN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	09/22/2034	Common Stock	24,155	$1.43	D
Stock Option (right to buy)	⁽²⁾	10/30/2035	Common Stock	24,155	$2.43	D
Series A Convertible Preferred Stock	⁽³⁾	⁽³⁾	Common Stock	1,611	⁽³⁾	D
Series B Convertible Preferred Stock	⁽⁴⁾	⁽⁴⁾	Common Stock	2,504	⁽⁴⁾	D

Explanation of Responses:

1. Granted to the Reporting Person on September 23, 2024. The stock options vest in 1/36 monthly increments, with the first vesting date on January 11, 2024, subject to the Reporting Person's continued service to the Issuer on each vesting date.

2. Granted to the Reporting Person on October 31, 2025. The stock options vest in 1/36 monthly increments, with the first vesting date on September 29, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.

3. The Series A Convertible Preferred Stock (the "Series A Preferred Stock") is convertible into one share of Common Stock at any time at the option of the holder. The Series A Preferred Stock will automatically convert immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Series A Preferred Stock has no expiration date.

4. The Series B Convertible Preferred Stock (the "Series B Preferred Stock") is convertible into one share of Common Stock at any time at the option of the holder. The Series B Preferred Stock will automatically convert immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Series B Preferred Stock has no expiration date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Alex Schwartz, Attorney-in-fact	10/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR